Our People

C. Glenn Begley, MBBS, PhD, FRACP Clinical Advisor

Dr. Begley is Chief Scientific Officer and Senior Vice President of Research for TetraLogic Pharma. Until January 2012, Dr. Begley was Vice-President and Global Head of Hematology and Oncology Research at Amgen Inc. He joined Amgen in 2002, and was responsible for building the Hematology and Oncology research program. He also had scientific responsibility for marketed Amgen products which involved preparation and presentations at multiple FDA face-to-face meetings and FDA Drug Advisory Committee meetings.

Before joining Amgen, he had over 20 years of clinical experience in medical oncology and hematology. His early studies first described human G-CSF, and in later clinical studies, he first demonstrated that G-CSF-"mobilized" blood stem cells and hastened hematopoietic recovery compared with bone marrow transplantation. This finding revolutionized the approach to clinical hematopoietic cell transplantation. His basic research focused on hematopoietic regulation. He defined the function of the CSFs and their receptors using animal models. He was the first to molecularly clone the transcription factor SCL, and demonstrate its critical role in leukemia and normal hematopoiesis.

Dr. Begley is Board Certified in Australia as a Medical Oncologist (F.R.A.C.P.), Laboratory Hematologist (F.R.C.P.A., Australia; F.R.C.Path, United Kingdom) and has a Ph.D. in cellular and molecular biology. He has published over 200 scientific papers and was elected to the prestigious Association of American Physicians in 2008.

Back to All